Kim Yahya

Kim Yahya is currently the Director of Bioanalysis at TAUC3 Biologics, focusing on precision immunotherapy for tau-related frontotemporal dementia and progressive supranuclear palsy. Prior experience includes serving as Principal Scientist at WaveBreak, leading a team in the production and characterization of challenging amyloid proteins, and at Avacta, where expertise in immuno-oncology bispecific biotherapeutics contributed to preclinical development. Kim Yahya also held positions as Senior Protein Scientist at LabGenius and Scientist at Sartorius Stedim BioOutsource, where skills in biosimilar testing and drug screening were honed. Early career contributions as a Postdoctoral Research Fellow at The Institute of Cancer Research and King's College London involved protein production and biophysical characterizations. Kim Yahya earned a DPhil in Biochemistry from the University of Oxford.